A Phase 4 interventional study of Dexamethasone and Methylprednisolone in Sacroiliac Joint Dysfunction and Sacro-Iliac Spondylosis, sponsored by University of New Mexico. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-11-06.
Sponsored by University of New Mexico · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Spondylosis with a site in United States — 17 open to participants now, 18 under way, none of them phase 3. Spondylosis · United States.
Among the 63 studies in Spondylosis with a site in United States, this one is the 2nd largest by planned enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2024, is one of 5 in phase 4, reaches primary completion later than 7 of the 17 other live ones, and was the 53rd registered.
142 studies on the registry are indexed under Spondylosis; 41 are open to participants now.
Browse Spondylosis studies →17 of the 63 studies in Spondylosis with a site in United States are open now. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 18+
Georgetown University · Sites in United States
Ages 18+
EicOsis Human Health Inc. · Sites in United States
Ages 18+
University of Arkansas · Sites in United States
Ages 18+
R3 Stem Cell · Sites in United States
Ages 20+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Spondylosis studies recruiting now, 12 (44%) set no upper age limit and 10 (37%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 230 is above the median of 60 across 101 interventional studies indexed under Spondylosis.
Median enrollment 45 across the 45 interventional studies, 78 across the 18 observational. Of the 37 that completed or were terminated, 14 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 63 have an industry lead sponsor. The 10 most frequent:
University of New Mexico is the lead sponsor of 313 studies on the registry; 27 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 23 (88%) have results posted.
University of New Mexico has 1 study filed under Spondylosis — fewer than ten, so there is no comparison to draw.
8 of the studies in Spondylosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04140344Duke UniversityThe NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions | 2026-12 |
| NCT06268704University of New MexicoParticulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection | 2027-01-01 |
| NCT05356286University of California, Los AngelesRecording of Intraoperative Spinal Cord Stimulation and Monitoring | 2027-01-22 |
| NCT05029726John O'TooleRegional Anesthesia in Minimally Invasive Lumbar Spine Surgery | 2027-02-01 |
| NCT06361485R3 Stem CellSafety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain | 2027-03-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 63 studies in Spondylosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will compare two different corticosteroids (dexamethasone and methylprednisolone) for use in sacroiliac joint injections to treat SI joint pain.
Patients who are screened for inclusion will be randomized into one of two groups; dexamethasone or methylprednisolone. Patients will report their pain immediately after the procedure to confirm the diagnosis of sacroiliac joint pain, then be followed for three months to compare the efficacy and safety of the two medications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this arm will receive an injection of 1 milliliter of 2% lidocaine with 10 milligrams of dexamethasone to one or both sacroiliac joints. If participants initially achieve relief from the injection but then have a return of pain they may be offered a second injection with the same drug at the same dose.
Drug: Dexamethasone · Drug: 2% Lidocaine HCl Injection
Patients in this arm will receive an injection of 1 milliliter of 2% lidocaine with 40 milligrams of methylprednisolone to one or both sacroiliac joints. If participants initially achieve relief from the injection but then have a return of pain they may be offered a second injection with the same drug at the same dose.
Drug: Methylprednisolone · Drug: 2% Lidocaine HCl Injection
This is a non-particulate steroid commonly used to treat SI joint pain.
Also known as: Ozurdex, Maxidex, DexPak
This is a particulate steroid commonly used to treat SI joint pain.
Also known as: Solu-medrol, Depo-Medrol, Medrol
Lidocaine is a local anesthetic used in SI joint injection procedures to numb the procedure site and helps to confirm SI joint dysfunction when injected with the steroid medication into the SI joint.
Also known as: Lignocaine, Xylocaine
Pain using Numeric Pain Rating Score
Numeric pain rating score is an 11 point scale (0-10) filled out on a form indicating the degree to which the patient experiences pain to assess efficacy of the injection. In this scale a 0, the minimum score, indicates no pain at all with a 10, the maximum score, being the worst pain imaginable. In this study a 50% or greater reduction in numeric pain rating score is considered a successful outcome while failure to achieve at least a 50% improvement as compared to their numeric pain rating score prior to the procedure is considered a poor outcome.
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Jan 2027, 33 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone